All relevant data are within the paper.

Introduction {#sec001}
============

Alagille syndrome (ALGS; OMIM 118450) is an autosomal dominant disorder that results from defects in the Notch signaling pathway, typically via mutations in the gene encoding a ligand for Notch receptors, *JAGGED1* (*JAG1*). ALGS is associated with a wide variety of clinical features and manifestations, including abnormalities of the liver, heart, skeleton, eyes, kidneys, and facial features \[[@pone.0130355.ref001]\]. It is one of the most common causes of pediatric chronic liver disease and occurs with a minimal estimated frequency of 1 in 70,000--100,000 newborn infants \[[@pone.0130355.ref002]\]. The classical criteria for ALGS diagnosis include bile duct paucity on liver biopsy in association with three of the following: cholestasis, congenital heart disease, vertebral abnormalities, characteristic facial features, and posterior embryotoxon \[[@pone.0130355.ref003]\]. However, the advent of molecular diagnostic testing has led to a revision of diagnostic criteria for ALGS \[[@pone.0130355.ref004]\].

*JAG1* mutations and/or ALGS clinical features have been reported in various populations, such as American, European, Australian, and Japanese \[[@pone.0130355.ref005]--[@pone.0130355.ref010]\]. Nearly 500 *JAG1* mutations have been identified (HGMD Professional 2015.1). Approximately 94% of patients with a clinically confirmed diagnosis of ALGS carry *JAG1* mutations, of which 60--70% are *de novo* \[[@pone.0130355.ref011]--[@pone.0130355.ref013]\]. We previously reported a case series of Chinese ALGS patients with a *de novo* mutation frequency of 100% (5/5), including an atypical disease case \[[@pone.0130355.ref014]\]. To further characterize *JAG1* mutations and their origins in Chinese patients with ALGS, we performed a genetic study on a cohort of sporadic patients with at least two of the six major clinical features (chronic cholestasis, cardiac murmur, skeletal abnormalities, ocular abnormalities, a characteristic face, and renal abnormalities).

Materials and Methods {#sec002}
=====================

Subjects {#sec003}
--------

This study included 91 patients (37 female and 54 male, including 17 reported previously \[[@pone.0130355.ref014]\]) from 89 unrelated families referred to the pediatric liver disease clinic of Children's Hospital of Fudan University between January 2010 and December 2014; cases 30 and 70 were twins, and cases 59 and 69 were brothers.

Diagnostic criteria for ALGS and evaluations of clinical features {#sec004}
-----------------------------------------------------------------

All patients had at least two clinical features of ALGS ([Table 1](#pone.0130355.t001){ref-type="table"}). The diagnosis of ALGS was based on the presence of bile duct paucity and at least three major clinical features, including chronic cholestasis, cardiac murmur, skeletal abnormalities, ocular abnormalities, and a characteristic face, or at least four of six major clinical features (chronic cholestasis, cardiac murmur, skeletal abnormalities, ocular abnormalities, a characteristic face and renal abnormalities) in the absence of paucity of bile ducts \[[@pone.0130355.ref004]\].

10.1371/journal.pone.0130355.t001

###### Pathologic and clinical Alagille syndrome features of 91 patients.

![](pone.0130355.t001){#pone.0130355.t001g}

  Patient No.                                 Interlobular bile duct paucity   Cholestasis   Cardiac murmur   Skeletal abnormalities   Characteristic face   Posterior embryotoxon   Kidney abnormalities   Total clinical features, *n*
  ------------------------------------------- -------------------------------- ------------- ---------------- ------------------------ --------------------- ----------------------- ---------------------- ------------------------------
  *1[\*](#t001fn002){ref-type="table-fn"}*    \+                               \+            \+               \+                       \+                    \+                      \+                     6
  *2[\*](#t001fn002){ref-type="table-fn"}*    NA                               \+            \+               \+                       \+                    \+                      \+                     6
  *3[\*](#t001fn002){ref-type="table-fn"}*    \+                               \+            \+               \+                       \+                    \+                      \-                     5
  *4[\*](#t001fn002){ref-type="table-fn"}*    \+                               \+            \+               \+                       \+                    \+                      \-                     5
  *5[\*](#t001fn002){ref-type="table-fn"}*    \+                               \+            \+               \-                       \+                    \+                      \+                     5
  6[\*](#t001fn002){ref-type="table-fn"}      \+                               \+            \+               \+                       \+                    \+                      \-                     5
  7[\*](#t001fn002){ref-type="table-fn"}      \+                               \+            \+               \+                       \+                    \+                      \-                     5
  *8[\*](#t001fn002){ref-type="table-fn"}*    \-                               \+            \+               \+                       \+                    \+                      \-                     5
  9[\*](#t001fn002){ref-type="table-fn"}      \+                               \+            \+               \+                       \+                    \+                      \-                     5
  10[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \+                      \-                     5
  11[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \+                      \-                     5
  12[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      \+                     5
  13[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \+                      \-                     5
  14[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \+                      \-                     5
  15[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      \+                     5
  16[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \+                      \-                     5
  17[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \+                      \-                     5
  18[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      \+                     5
  19[\*](#t001fn002){ref-type="table-fn"}     \+                               \+            \+               \+                       \+                    NA                      \+                     5
  *20[\*](#t001fn002){ref-type="table-fn"}*   NA                               \+            \+               \+                       \+                    \+                      NA                     5
  *21[\*](#t001fn002){ref-type="table-fn"}*   \+                               \+            \+               \+                       \+                    \+                      NA                     5
  22[\*](#t001fn002){ref-type="table-fn"}     \-                               \+            \+               \+                       \+                    \+                      NA                     5
  *23[\*](#t001fn002){ref-type="table-fn"}*   NA                               \+            \+               \+                       \+                    \+                      NA                     5
  24[\*](#t001fn002){ref-type="table-fn"}     \+                               \+            \+               \-                       \+                    \+                      \-                     4
  *25[\*](#t001fn002){ref-type="table-fn"}*   \+                               \+            \-               \+                       \+                    \-                      \+                     4
  26[\*](#t001fn002){ref-type="table-fn"}     \+                               \+            \+               \+                       \+                    \-                      \-                     4
  *27[\*](#t001fn002){ref-type="table-fn"}*   \-                               \+            \+               \+                       \+                    \-                      \-                     4
  28[\*](#t001fn002){ref-type="table-fn"}     \-                               \+            \+               \+                       \+                    \-                      \-                     4
  29[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      \-                     4
  30[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      \-                     4
  31[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    \-                      \+                     4
  32[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      \-                     4
  33[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \-                    \+                      \-                     4
  34[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    \+                      \-                     4
  35[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      \-                     4
  36[\*](#t001fn002){ref-type="table-fn"}     \+                               \+            \+               \+                       \+                    \-                      NA                     4
  *37[\*](#t001fn002){ref-type="table-fn"}*   \-                               \+            \+               \-                       \+                    \+                      NA                     4
  38[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      NA                     4
  39[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      NA                     4
  40[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    NA                      \-                     4
  41[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    NA                      \-                     4
  42[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    NA                      \-                     4
  43[\*](#t001fn002){ref-type="table-fn"}     \+                               \+            \+               \+                       \+                    NA                      \-                     4
  44[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \+                    \-                      NA                     4
  45[\*](#t001fn002){ref-type="table-fn"}     \-                               \+            \+               \+                       \+                    \-                      NA                     4
  *46[\*](#t001fn002){ref-type="table-fn"}*   \+                               \+            \+               \+                       \+                    NA                      NA                     4
  *47[\*](#t001fn002){ref-type="table-fn"}*   \+                               \+            \+               \+                       \-                    \-                      \-                     3
  48[\*](#t001fn002){ref-type="table-fn"}     \+                               \+            \+               \+                       \-                    NA                      NA                     3
  49                                          NA                               \+            \+               \+                       \+                    \+                      \-                     5
  50                                          \-                               \+            \+               \+                       \+                    \+                      \-                     5
  *51*                                        \+                               \+            \+               \+                       \+                    \+                      \-                     5
  *52*                                        NA                               \+            \+               \+                       \+                    \-                      \+                     5
  53                                          \+                               \+            \-               \+                       \+                    \-                      \+                     4
  54                                          NA                               \+            \+               \-                       \+                    \+                      \-                     4
  55                                          \+                               \+            \+               \-                       \+                    \-                      \-                     3
  56[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \-                    \-                      \-                     3
  57[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \-                    \-                      \-                     3
  58[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \-                    \-                      \-                     3
  59[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \-                    \+                      \-                     3
  60[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    \-                      \-                     3
  61[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \-               \+                       \+                    \-                      \-                     3
  62[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \-               \+                       \+                    \-                      \-                     3
  63                                          NA                               \+            \+               \+                       \-                    \-                      \-                     3
  64                                          \-                               \+            \+               \-                       \+                    \-                      \-                     3
  65                                          NA                               \+            \+               \-                       \-                    \+                      \-                     3
  66[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    \-                      NA                     3
  67[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \-               \+                       \+                    \-                      NA                     3
  68[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \-                    \-                      NA                     3
  69[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    \-                      NA                     3
  70[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    NA                      \-                     3
  71[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    NA                      \-                     3
  72[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \-               \+                       \+                    NA                      \-                     3
  73[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \-                       \+                    NA                      \-                     3
  74[\*](#t001fn002){ref-type="table-fn"}     \-                               \+            \+               \+                       \-                    NA                      NA                     3
  75[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       \-                    NA                      NA                     3
  76[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \+               \+                       NA                    NA                      NA                     3
  77                                          NA                               \+            \+               \+                       \-                    NA                      NA                     3
  78[\*](#t001fn002){ref-type="table-fn"}     \-                               \+            \+               \-                       \-                    \-                      \-                     2
  79                                          NA                               \+            \-               \-                       \+                    \-                      \-                     2
  80                                          \+                               \+            \+               \-                       \-                    \-                      \-                     2
  *81[\*](#t001fn002){ref-type="table-fn"}*   NA                               \+            \-               \+                       \-                    \-                      NA                     2
  82[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \-               \-                       \+                    NA                      \-                     2
  83                                          NA                               \+            \-               \-                       \-                    NA                      \+                     2
  84                                          NA                               \+            \-               \+                       \-                    \-                      NA                     2
  85                                          NA                               \+            \+               \-                       \-                    NA                      \-                     2
  86                                          NA                               \+            \+               \-                       \-                    NA                      \-                     2
  87                                          NA                               \+            \-               NA                       \+                    \-                      \-                     2
  88[\*](#t001fn002){ref-type="table-fn"}     NA                               \+            \-               \+                       \-                    NA                      NA                     2
  89                                          NA                               \+            \+               \-                       \-                    NA                      NA                     2
  90                                          NA                               \-            \+               NA                       \-                    \+                      NA                     2
  91                                          NA                               \+            \+               NA                       \-                    NA                      \-                     2
  Total                                       31                               91            91               88                       90                    69                      66                     

NA: not available.

\**JAG1* mutation detected; cases previously reported are in italic font.

Cases 1--55 met the clinical diagnostic criteria for Alagille syndrome; cases 56--91 were considered as clinically suspected cases.

Ninety of the 91 patients were initially referred to our center primarily for cholestasis, including 83 cases with jaundice and 7 cases presenting with pruritus and elevated serum transaminase with high γ-glutamyl transpeptidase. One case initially presented with hepatomegaly. The majority of physical examinations were performed by one author (JSW). The presence of a heart murmur or ALGS facial features prompted additional examinations, including echocardiography, abdominal ultrasound, radiography of the spine, and ophthalmologic examination. Results of these examinations, along with clinical features and liver function test results were retrospectively obtained from medical records. Liver biopsy was performed on 31 patients. Histology of all patients was assessed by the same experienced liver pathologist.

Mutation detection {#sec005}
------------------

With the approval of the ethics committee of Children's Hospital of Fudan University and written informed consent from parents, \~1 mL of peripheral blood was obtained from each participant and his/her parents (if available). Genomic DNA from peripheral blood lymphocytes was extracted using commercial extraction kits. All 26 coding exons of *JAG1* (RefSeq NM_000214.2) including at least 100 bp of adjacent intronic sequence were amplified by PCR (primer sequences available on request), and detected by laser-induced fluorescence on an ABI Prism 3130 or 3500 Genetic Analyzer (Applied Biosystems of Thermo Fisher Scientific, Waltham, MA, USA). Sequence analysis was performed using BIOEDIT software (North Carolina State University, Raleigh, NC, USA) and doubly checked by two investigators. All sequences were compared using BLAST against genomic sequences from the National Center for Biotechnology Information. If no mutation was detected by sequencing, multiplex-ligation-dependent probe amplification (MLPA) dosage analysis was carried out to look for partial or whole gene deletions. MLPA analysis was performed according to the manufacturer's instructions using the P184 MLPA kit available from MRC-Holland (Amsterdam, Netherlands).

The pathogenicity of missense variants was analyzed using Mutation Taster (<http://www.mutationtaster.org>) and Polyphen-2 (<http://genetics.bwh.harvard.edu/pph-2>). Additional factors that were considered include: (a) absence in the general population; (b) novel appearance and disease phenotype from the family pedigree; (c) absence of any other mutation in *JAG1* that could be responsible for the clinical phenotype; and (d) previous independent occurrence in an unrelated patient.

Results {#sec006}
=======

Mutations and polymorphisms {#sec007}
---------------------------

Sequence analysis was successful for all cases, and an MLPA dosage result was obtained for 22 cases in which no mutation or only a missense variant was identified by sequencing and sufficient DNA was available. Sequencing and MLPA identified 62 different mutations in these patients. The mutations were unique among cases, with the exceptions of c.439C\>T, c.439+1G\>A, c.703C\>T, c.1382_1383delAC, c.2698C\>T, and c.2990C\>A, which occurred in two cases, and entire gene deletions in three cases. Fifty-nine mutations were identified by sequencing, including frameshift (*n* = 34), nonsense (*n* = 12), splicing site (*n* = 7), and missense (*n* = 6) mutations. Of these mutations, 72.6% (45/62) were novel ([Table 2](#pone.0130355.t002){ref-type="table"}).

10.1371/journal.pone.0130355.t002

###### Summary of *JAG1* mutations identified in patients.

![](pone.0130355.t002){#pone.0130355.t002g}

  Patient No.   Sex        Mutation                                                     Location           Domain      Origin
  ------------- ---------- ------------------------------------------------------------ ------------------ ----------- -----------
  *1*           *Male*     ***c*.*1868delG*, *p*.*G623EfsX118*, *het***                 Exon 14            EGF         ND
  *2*           *Female*   *c*.*439C\>T*, *p*.*Q147X*, *het*                            Exon 3             5´ of DSL   ND
  *3*           *Male*     ***c*.*866delG*, *p*.*G289AfsX121*, *het***                  Exon 6             EGF         *De novo*
  *4*           *Male*     ***c*.*1323_1326delCTGG*, *p*.*M443VfsX4*, *het***           Exon 10            EGF         ND
  *5*           *Female*   ***c*.*1771_1775delGTGCG1insT*, *p*.*V591CfsX149*, *het***   Exon 14            EGF         ND
  6             Female     **c.2628G\>A, p.W876X, het**                                 Exon 22            CR          *De novo*
  7             Female     **c.439+2dupT, het**                                         Intron 3                       *De novo*
  *8*           *Male*     ***c*.*550C\>T*, *p*.*R184C*, *het;*** *MLPA not done*       Exon 4             5´ of DSL   *De novo*
  9             Male       c.2572+1G\>T, het                                            Intron 21                      ND
  10            Female     **c.980_989delGGTATTCAGG, p.G327DfsX82, het**                Exon 7             EGF         ND
  11            Male       c.1007delC, p.A336VfsX76, het                                Exon 8             EGF         De novo
  12            Male       **c.2230delC, p.R744EfsX76, het**                            Exon 18            EGF         *De novo*
  13            Male       **c.2502delC, p.C835VfsX35, het**                            Exon 21            EGF         *De novo*
  14            Female     c.703C\>T, p.R235X, het                                      Exon 5             5´ of EGF   Paternal
  15            Female     c.2473C\>T, p.Q825X, het                                     Exon 21            EGF         Paternal
  16            Female     c.2698C\>T, p.R900X, het                                     Exon 23            CR          ND
  17            Female     **c.3140C\>A, p.S1047X, het**                                Exon 25            5´ of TM    *De novo*
  18            Male       entire gene deletion, het                                                                   ND
  19            Female     **c.1148_1149delGT, p.C383FfsX11, het**                      Exon 9             EGF         ND
  *20*          *Male*     ***c*.*3099_3100delCA*, *p*.*D1033EfsX5*, *het***            Exon 25            CR          *De novo*
  *21*          *Male*     *c*.*2230C\>T*, *p*.*R743X*, *het*                           Exon 18            EGF         ND
  22            Male       **c.1349-10_1353delTATTTTTTAGATATT, het**                    Intron 10-Exon11               *De novo*
  *23*          *Female*   *c*.*1156G\>A*, *p*.*G386R*, *het; MLPA not done*            Exon 9             EGF         ND
  24            Male       **c.410delA, p.E137GfsX24, het**                             Exon 3             5´ of DSL   ND
  *25*          *Male*     *c*.*693_694delAG*, *p*.*R231SfsX8*, *het*                   Exon 4             5´ of DSL   ND
  26            Male       **c.1468G\>T, p.E490X, het**                                 Exon 12            EGF         *De novo*
  *27*          *Male*     *c*.*439+1G\>A*, *het*                                       Intron 3                       *De novo*
  28            Male       **Ex.1-5 deletion, het**                                                                    ND
  29            Male       **c.755+2T\>G, het**                                         Intron 5                       Maternal
  30            Female     **c.1382_1383delAC, p.D461GfsX8, het**                       Exon 11            EGF         *De novo*
  31            Male       **c.1842delC, p.C615VfsX128, het**                           Exon 14            EGF         *De novo*
  32            Male       **c.1859delG, p.G620AfsX123, het**                           Exon 14            EGF         *De novo*
  33            Male       **c.2909_2913delTGTCA, p.M970TfsX11, het**                   Exon 23            CR          *De novo*
  34            Female     **c.2070_2073dupCTGT, het**                                  Exon 16            EGF         ND
  35            Female     **c.3088_3089insG, p.E1030GfsX4, het**                       Exon 25            5´ of TM    ND
  36            Male       c.439C\>T, p.Q147X, het                                      Exon 3             5´ of DSL   *De novo*
  *37*          *Female*   ***c*.*766G\>T*, *p*.*G256C*, *het;*** *MLPA not done*       Exon 6             EGF         *De novo*
  38            Male       **c.2026T\>G, p.C676G, het** and no mutation by MLPA         Exon 16            EGF         *De novo*
  39            Male       **c.3008_3020insAGCCTTCCCCTTC, p.E1030GfsX4, het**           Exon 24            CR          Maternal
  40            Female     c.2225_2226delTA, p.I742SfsX5, het                           Exon 17            EGF         Maternal
  41            Female     **c.702C\>A, p.C234X, het**                                  Exon 5             5´ of EGF   *De novo*
  42            Female     **c.238A\>G, p.K80E, het** and no mutation by MLPA           Exon 2             5´ of DSL   *De novo*
  43            Female     entire gene deletion, het                                                                   ND
  44            Male       entire gene deletion, het                                                                   ND
  45            Female     **Ex.2-26 deletion, het**                                                                   ND
  *46*          *Female*   ***c*.*2791_2792insA*, *p*.*T931NfsX19*, *het***             Exon 23            CR          ND
  *47*          *Male*     ***c*.*819delC*, *p*.*H273QfsX*, *het***                     Exon 6             EGF         ND
  48            Female     c.1899_1900delTG, p.C633X, het                               Exon 15            EGF         *De novo*
  49            Female     No mutation by sequencing and MLPA                                                          
  50            Female     No mutation by sequencing and MLPA                                                          
  *51*          *Male*     *No mutation by sequencing; MLPA not done*                                                  
  *52*          *Male*     *No mutation by sequencing; MLPA not done*                                                  
  53            Male       No mutation by sequencing and MLPA                                                          
  54            Female     No mutation by sequencing and MLPA                                                          
  55            Male       No mutation by sequencing; MLPA not done                                                    
  56            Male       c.1499delG, p.G500VfsX64, het                                Exon 12            EGF         ND
  57            Male       **c.2314delG, p.E772KfsX48, het**                            Exon 18            EGF         ND
  58            Male       **c.3244_3256delATCTGTTGCTTGG, het**                         Exon 26            TM          *De novo*
  59            Male       **c.2990C\>A, p.S997X, het**                                 Exon 24            CR          Maternal
  60            Male       c.3031G\>T, p.E1011X, het                                    Exon 24            5´ of TM    ND
  61            Female     **c.2345-2A\>G, het**                                        Intron 18                      *De novo*
  62            Female     **c.2071T\>A, p.C691S, het** and no mutation by MLPA         Exon 16            EGF         ND
  63            Female     No mutation by sequencing and MLPA                                                          
  64            Male       No mutation by sequencing and MLPA                                                          
  65            Male       No mutation by sequencing and MLPA                                                          
  66            Male       **c.897delC, p.C300VfsX112, het**                            Exon 7             EGF         ND
  67            Male       **c.3194_3195delGA, p.R1065NfsX43, het**                     Exon 25            5´ of TM    *De novo*
  68            Male       **c.1281_1282insT, p.K428X, het**                            Exon 10            EGF         *De novo*
  69            Male       **c.2990C\>A, p.S997X, het**                                 Exon 24            CR          Maternal
  70            Female     **c.1382_1383delAC, p.D461GfsX8, het**                       Exon 11            EGF         *De novo*
  71            Male       **c.1931delG, p.C644SfsX99, het**                            Exon 15            EGF         Paternal
  72            Male       **c.2287_2288insAACG, p.G763EfsX24, het**                    Exon 18            EGF         *De novo*
  73            Female     **c.1885+3_1885+4insGT, het**                                Intron 14                      *De novo*
  74            Male       **c.65delG, p.C22LfsX24, het**                               Exon 1             5´ of DSL   ND
  75            Female     **c.1118delC, p.T373KfsX39, het**                            Exon 8             EGF         *De novo*
  76            Male       c.2698C\>T, p.R900X, het                                     Exon 23            CR          *De novo*
  77            Male       No mutation by sequencing; MLPA not done                                                    
  78            Male       c.703C\>T, p.R235X, het                                      Exon 5             5´ of EGF   ND
  79            Female     No mutation by sequencing and MLPA                                                          
  80            Male       No mutation by sequencing; MLPA not done                                                    
  *81*          *Female*   *c*.*826delT*, *p*.*C276VfsX134*, *het*                      Exon 6             EGF         ND
  82            Male       c.439+1G\>A, het                                             Intron 3                       ND
  83            Male       No mutation by sequencing and MLPA                                                          
  84            Female     No mutation by sequencing and MLPA                                                          
  85            Female     No mutation by sequencing and MLPA                                                          
  86            Male       No mutation by sequencing; MLPA not done                                                    
  87            Female     No mutation by sequencing and MLPA                                                          
  88            Male       c.3006C\>A, p.C1002X, het                                    Exon 24            CR          ND
  89            Male       No mutation by sequencing and MLPA                                                          
  90            Female     No mutation by sequencing and MLPA                                                          
  91            Male       No mutation by sequencing; MLPA not done                                                    

Novel variants are in bold font; cases previously reported are in italic font. Conserved regions of JAG1 protein include the signal peptide (SP), the delta-serrate-lin12-like region (DSL), epidermal growth factor (EGF)-like repeats, the cysteine-rich (CR) region, and the transmembrane (TM) domain; 5´ of DSL: the region between SP and DSL domain; 5´ of TM: the region between CR and TM.

het: heterozygous; MPLA: multiplex-ligation-dependent probe amplification; ND: not done.

At the time of the study, seven synonymous and three missense variants were regarded as polymorphisms. Two of the missense variants were not seen in 1000 Genomes and single-nucleotide polymorphism (SNP) databases ([Table 3](#pone.0130355.t003){ref-type="table"}); c.1511A\>G (p.N504S) was identified in case 67 and inherited from his healthy mother, and c.3178C\>T (p.R1060W) was identified in case 29 and inherited from his mildly affected mother. Both of these cases had simultaneous, definite disease-causing mutations. Therefore, c.1511A\>G and c.3178C\>T were considered as rare SNPs, rather than disease-causing mutations.

10.1371/journal.pone.0130355.t003

###### *JAG1* polymorphisms identified in these cases.

![](pone.0130355.t003){#pone.0130355.t003g}

  Polymorphism                                                Amino acid     Location   dbSNP identifier   MAF (global)
  ----------------------------------------------------------- -------------- ---------- ------------------ --------------
  c.267G\>A                                                   p.G89G         Exon 2     rs1051415          0.08
  c.588C\>T                                                   p.C196C        Exon 4     rs1801138          0.16
  c.765C\>T                                                   p.Y255Y        Exon 6     rs1131695          0.41
  [^a^c](#t003fn001){ref-type="table-fn"}.1511A\>G            p.N504S        Exon 6     \-                 \-
  c.2214A\>C                                                  p.T738T        Exon 17    rs1801140          0.09
  c.2612C\>G                                                  p.P871R        Exon 22    rs35761929         0.04
  c.3141G\>A                                                  p.S1047S       Exon 25    rs202075581        \< 0.01
  [^**b**^](#t003fn002){ref-type="table-fn"} **c.3178C\>T**   **p.R1060W**   Exon 25    \-                 \-
  c.3417T\>C                                                  p.Y1139Y       Exon 26    rs1051419          0.67
  c.3528C\>T                                                  p.Y1176Y       Exon 26    rs1051421          0.21

^a^identified in case 67 and maternal;

^b^identified in case 29 and maternal;

Novel variant is in bold font.

dbSNP: single nucleotide polymorphism database; MAF: minor allelic frequency.

Predicted effects of missense variants {#sec008}
--------------------------------------

*In silico* studies using two different functional prediction programs (Mutation Taster and Polyphen-2) predicted a deleterious impact from missense variants c.238A\>G (p.K80E), c.550C\>T (p.R184C), c.766G\>T (p.G256C), c.1156G\>A (p.G386R), c.2026T\>G (p.C676G), c.2071T\>A (p.C691S), c.2612C\>G (p.P871R), and c.3178C\>T (p.R1060W) ([Table 4](#pone.0130355.t004){ref-type="table"}). Mutation c.1511A\>G (p.N504S) was classified as disease-causing by Mutation Taster, but benign by Polyphen-2.

10.1371/journal.pone.0130355.t004

###### Deduced effects of missense variants.

![](pone.0130355.t004){#pone.0130355.t004g}

  Missense variants             Mutation Taster   Polyphen-2                       
  ----------------------------- ----------------- ------------ ------------------- -------
  c.238A\>G, p.K80E             Disease-causing   0.999        Probably damaging   0.997
  *c*.*550C\>T*, *p*.*R184C*    Disease-causing   0.999        Probably damaging   1.000
  *c*.*766G\>T*, *p*.*G256C*    Disease-causing   0.999        Probably damaging   1.000
  *c*.*1156G\>A*, *p*.*G386R*   Disease-causing   0.999        Probably damaging   0.997
  c.1511A\>G, p.N504S           Disease-causing   0.999        Benign              0.007
  c.2026T\>G, p.C676G           Disease-causing   0.999        Probably damaging   1.000
  c.2071T\>A, p.C691S           Disease-causing   0.999        Probably damaging   0.973
  c.2612C\>G, p.P871R           Disease-causing   0.999        Possibly damaging   0.703
  c.3178C\>T, p.R1060W          Disease-causing   0.999        Possibly damaging   0.586

Cases previously reported are in italic font.

Distribution of JAG1 point and frameshift mutations {#sec009}
---------------------------------------------------

Mutations identified by sequencing occurred throughout the coding sequence of *JAG1*, and no common mutations were detected. The sequencing of eleven exons (exons 3, 5, 6, 11, 14, 16, 18, 21, and 23--25) of *JAG1* would detect a majority (69.2%) of the point and frameshift mutations.

Segregation testing {#sec010}
-------------------

A total of 37 sets of parents' samples were available. Segregation testing revealed that 30/37 (81.1%) mutations arose *de novo*, whereas 7/37 (18.9%) were maternally (*n* = 4) or paternally (*n* = 3) inherited ([Table 2](#pone.0130355.t002){ref-type="table"}).

Mutation detection rate {#sec011}
-----------------------

Overall, a mutation in *JAG1* was identified in 70/91 (76.9%) cases. Fifty-five patients met the diagnostic criteria for ALGS; 20 patients with evidence of bile duct paucity had at least three clinical features of ALGS, and the remaining 35 patients had at least four clinical features. *JAG1* mutations were identified in 87.3% (48/55) of them ([Table 1](#pone.0130355.t001){ref-type="table"}).

Thirty-six patients who did not meet the diagnostic criteria were considered as suspected ALGS cases. Although at least one examination was missing in 23 of these cases, 20 patients did not meet the clinical diagnostic criteria for definite ALGS (cases 56--65 and 78--87); *JAG1* mutations were detected in 50.0% (10/20) of them ([Table 1](#pone.0130355.t001){ref-type="table"}).

Discussion {#sec012}
==========

In this study, *JAG1* mutations were identified in 87.3% of clinically diagnosed ALGS patients and 50% of clinically suspected ALGS patients, indicating that *JAG1* mutations are the major cause of classical ALGS, but also cause sporadic atypical Chinese ALGS cases. The mutation spectrum in this Chinese cohort included 45 novel mutations in *JAG1*, which is different from other populations \[[@pone.0130355.ref011]--[@pone.0130355.ref013]\]. The majority (69.2%) of the point and frameshift mutations would be detected with sequencing of only eleven of the *JAG1* exons (exons 3, 5, 6, 11, 14, 16, 18, 21, and 23--25), while 62% of mutations were detected in ten exons (exons 2, 4, 5, 6, 9, 12, 17, 18, 23 and 24) in other populations \[[@pone.0130355.ref013]\]. With the exception of six missense mutations, all other identified mutations (34 frameshift, 12 nonsense, 7 splicing, and 3 gross deletion) were predicted to result in a truncated protein.

According to the segregation testing, 81.1% of the mutations were *de novo*, which is higher than reported previously \[[@pone.0130355.ref006], [@pone.0130355.ref008], [@pone.0130355.ref011], [@pone.0130355.ref015]\]. Moreover, a frameshift mutation was identified in case 11, and his two brothers and one sister all died of suspected ALGS, though the sequencing of *JAG1* in his parents was normal, despite the fact that his mother had facial features characteristic of ALGS. We speculate that germline mosaicism occurred in this family, and sequencing only the DNA from blood samples failed to identify the mutation. Giannakudis *et al* \[[@pone.0130355.ref016]\] reported that the frequency of mosaicism for *JAG1* mutations in ALGS is \> 8.2%, which should not be overlooked in genetic counseling.

In this cohort, nine missense variants were detected, including six mutations and three SNPs. Among these, c.550C\>T, c.766G\>T, and c.1156G\>A were reported in our previous study \[[@pone.0130355.ref014]\]. The *de novo* mutations c.238A\>G and c.2026T\>G, as well as c.2071T\>A, are novel and predicted to be deleterious; c.2026T\>G and c.2071T\>A are located in the conserved region of *JAG1*. As these three missense variants were not detected in the 1000 Genomes database and no other definite disease-causing mutations were identified, it is presumed that they are disease-causing mutations. Although the missense c.1511A\>G has been reported as a disease-causing mutation \[[@pone.0130355.ref013]\], it was considered as a rare SNP in this study as it was also detected in the unaffected mother and occurred along with a *de novo* deletion (c.3194_3195delGA) that would result in a truncated protein product. Similarly, the novel missense c.3178C\>T in case 29 was also considered as a rare SNP, as it occurred concurrently with a splicing mutation (c.755+2T\>G) resulting in congenital heart disease that was inherited from his mother. Additionally, c.2612C\>G (p.P871R) was detected with a concurrent nonsense mutation in case 59, with a global mean allelic frequency of 0.04 according to the SNP database. These findings provide evidence that segregation analysis is not only useful for genetic counseling, but also for judging the pathogenicity of missense variants.

The expression and penetrance of ALGS is variable, and genetic diagnosis can be useful for atypical patients. In this study, *JAG1* mutations were identified in patients with only two or three clinical features of ALGS, consistent with the report of Guegan *et al* \[[@pone.0130355.ref017]\], indicating that *JAG1* mutations can cause sporadic atypical ALGS, and thus gene testing should be conducted for patients who do not meet the diagnosis criteria of ALGS. The mutation detection rate for clinically definite ALGS patients in this study was 87.3%, which is lower than the 94% reported by Warthen *et al* \[[@pone.0130355.ref013]\]. However, it is not clear if the missense mutations detected in their study were disease causing, which could account for the mutation detection rate difference.

A limitation of the present study is that not all patients received identical clinical assessment, and samples were not obtained from all parents for segregation testing, which is inevitable in a retrospective study. Furthermore, the parents with *JAG1* mutations did not undergo full physical examinations.

In conclusion, the findings show that the vast majority of Chinese patients with clinical features of ALGS exhibit *JAG1* mutations. In addition, the mutation spectrum within this cohort is different from other populations. Finally, half of the patients presenting with just two or three clinical features of ALGS had *JAG1* mutations, indicating that *JAG1* testing will be useful for the diagnosis of atypical ALGS patients.
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